Purpose: @entity927 ( @entity928 ) is effective in reducing @entity190 in primary total knee replacement. Almost all studies used an intravenous form or a topical form. The aim of this study was to assess the blood sparing efficacy and the safety of oral @entity928 . Materials and Methods: All @entity1 with primary total knee replacement performed in our institute from January 2015 to October 2015 were eligible. Oral @entity928 group was given 1 g oral @entity928 2 hours before induction of anesthesia and 6 hours and 12 hours postoperatively. The control group was not given @entity928 . Results: There were 94 cases in the oral @entity928 group and 95 cases in the control group. There was no difference in the baseline characteristics. The oral @entity928 group had a significantly lower hemoglobin drop (1.7 g/dL vs. 2.5 g/dL), lower drain output (154 mL vs. 203 mL), lower hidden @entity190 (244 mL vs. 423 mL) and @entity190 (398 mL vs. 626 mL). There was no difference in transfusion rate (1.1% vs. 3.2%) and @entity1031 complication. There was no infection or mortality in both groups. Conclusions: Oral @entity928 is effective in reducing @entity190 in primary total knee replacement. It is a safe alternative to the intravenous or topical form.

Blood Sparing Efficacy of Oral XXXX in Primary Total Knee Arthroplasty: A Randomized Controlled Trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss', 'lower total blood loss'] @entity928 :: ('CHEBI:36088', 'Chemical') :: ['TXA'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic'] @entity927 :: ('MESH:D014148', 'Chemical') :: ['Tranexamic acid']
@entity927 :: (MESH:D014148,Chemical) :: ['Tranexamic Acid']
